In the HRD-positive, HER2-negative breast cancer in the GeparOLA study, olaparib with platinum performed better outcomes compared to standard neoadjuvant platinum chemotherapy in pCR with ORR of 80% and tolerable safety [141]. The gene discussed is ERBB2; the disease is breast carcinoma.